# Title

 Food and Drugs. PART 814â€”PREMARKET APPROVAL OF MEDICAL DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 814


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                         |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(250.0, 'USD')]                                                                                                                                                                                                                                                                               |
| Constraints | ['before', 'exceeds', 'more than', 'within', 'prior to', 'after', 'exceed', 'greater', 'at least', 'exactly']                                                                                                                                                                                  |
| Duration    | ['30.0 day', '5.0 year', '180.0 day', '21.0 year', '60.0 day', '21 year', '5.0 day', '135.0 day', '45.0 day', '75.0 day', '7.0 day', '3.0 month', '20 second']                                                                                                                                 |
| Condition   | ['until', 'not subject to', 'unless', 'where', 'subject to', 'when', 'if']                                                                                                                                                                                                                     |
| Entities    | ['United States', 'Such', 'Docket Number', 'G609', 'Disclosure', 'Application', 'Serious', 'Explain', 'Rockville, MD', 'Product', 'Postapproval', 'Scope', 'G112', 'Food', 'Unique', 'Purpose', 'Failure', 'Batch', 'Rm', 'Research', 'U.S', 'Information', 'Beltsville, MD', 'New', 'Denial'] |
| Date        | ['2013-12-23', '1971-05-01', '2018-01-23', '1976-05-28']                                                                                                                                                                                                                                       |


# Structured Analysis With Context

 


## Money

| Money          | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (250.0, 'USD') | The effectiveness of this device for this use has not been demonstrated;                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                |               (5) The amount to be charged for the device and, if the amount is more than $250, a report by an independent certified public accountant, made in accordance with the Statement on Standards for Attestation established by the American Institute of Certified Public Accountants, or in lieu of such a report, an attestation by a responsible individual of the organization, verifying that the amount charged does not exceed the costs of the device's research, development, fabrication, and distribution. |
| (250.0, 'USD') | If the amount charged is $250 or less, the requirement for a report by an independent certified public accountant or an attestation by a responsible individual of the organization is waived; and                                                                                                                                                                                                                                                                                                                               |
|                |               (6) Information concerning pediatric uses of the device, as required by &#167;&#8201;814.20(b)(13).                                                                                                                                                                                                                                                                                                                                                                                                                |


## Constraints

| Constraints   | Context                                                                                                                                       |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| before        | delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent                |
| before        | delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent                |
| after         | or to a device first marketed on, or after that date, which has been classified into class                                                    |
| before        | FDA as a new drug or antibiotic drug before May 28, 1976, and therefore is governed by                                                        |
| before        | the conditions to approval for any PMA approved before  the effective date of this part.                                                      |
| more than     | condition that affects or is manifested in not more than  8,000 individuals in the United States per year.                                    |
| greater       | analyses reveal risks of a different type or greater severity or frequency than previously included in submissions                            |
| within        | of the device: (i) The lot or batch within which a device was manufactured; (ii) The serial                                                   |
| before        | PMA file may not be disclosed by FDA before an approval order is issued to the applicant                                                      |
| before        | PMA file has been publicly disclosed or acknowledged before an order approving, or an order denying approval                                  |
| before        | PMA file has been publicly disclosed or acknowledged before an order approving, or an order denying approval                                  |
| before        | of portions of the safety and effectiveness data before an approval order or an order denying approval                                        |
| after         | public, as such disclosure is defined in &#167;&#8201;20.81. after                                                                            |
| after         | consumer complaint, and other similar data and information, after deletion of: (i) Any information that constitutes trade                     |
| within        | any regulatory purpose and is shown to fall within the exemption in &#167;&#8201;20.61 for trade secret or                                    |
| within        | to respond to a request for additional information within 180 days after the date FDA issues the                                              |
| after         | a request for additional information within 180 days after the date FDA issues the request or (B)                                             |
| within        | to respond to a request for additional information within 180 days after the date FDA issues the                                              |
| after         | a request for additional information within 180 days after the date FDA issues the request or (B)                                             |
| within        | not reside or have a place of business within the United States, the PMA shall be countersigned                                               |
| at least      | all copies of the PMA and identify in at least one copy the information that it believes to                                                   |
| within        | information in the application constitute valid scientific evidence within the meaning of &#167;&#8201;860.7 and provide reasonable assurance |
| more than     | of the device if the device consists of more than one physical component or ingredient; (iii) The properties                                  |
| within        | FDA's satisfaction that the action requested is included within the excluded category and meets the criteria for                              |
| before        | the concurrence of the appropriate FDA advisory committee before  requesting additional information.                                          |
| within        | If a master file is not referenced  within 5 years after the date that it is                                                                  |
| after         | master file is not referenced within 5 years after the date that it is submitted to FDA,                                                      |
| after         | applicant shall submit these reports&#8212; (1) 3 months after  the filing date,                                                              |
| within        | written response to FDA's request is not received within 180 days of the date of the request,                                                 |
| after         | applicant may resubmit a PMA or PMA supplement after  withdrawing it or                                                                       |
| after         | applicant may resubmit a PMA or PMA supplement after  withdrawing it or                                                                       |
| after         | applicant may resubmit a PMA or PMA supplement after  withdrawing it or                                                                       |
| after         | not require a PMA supplement under this paragraph. after                                                                                      |
| before        | PMA supplement for review and approval by FDA before making a change affecting the safety or effectiveness                                    |
| after         | applicant may make a change in a device after FDA's approval of a PMA for the device                                                          |
| after         | the date that such changes are being effected. after                                                                                          |
| prior to      | may be placed into effect by the applicant prior to the receipt under &#167;&#8201;814.17 of a written FDA                                    |
| before        | a periodic report, the change may be made before  it is reported to FDA.                                                                      |
| after         | supplement, the change may be made 30 days after FDA files the 30-day PMA supplement unless FDA                                               |
| after         | therefore, will not be deemed approved 30 days after  receipt.                                                                                |
| after         | The manufacturer may distribute the device 30 days  after the date on which FDA receives the 30-day                                           |
| within        | the 30-day notice, unless FDA notifies the applicant within 30 days from receipt of the notice that                                           |
| after         | Within 180 days  after receipt of an application that is accepted for                                                                         |
| after         | Within 180 days  after receipt of an application that is accepted for                                                                         |
| after         | Within 45 days  after a PMA is received by FDA, the agency                                                                                    |
| within        | FDA receives the resubmission; (2) Request in writing within 10 working days of the date of receipt                                           |
| within        | FDA will hold the informal conference  within 10 working days of its receipt of the                                                           |
| within        | FDA will hold the informal conference  within 10 working days of its receipt of the                                                           |
| after         | its decision on filing within 5 working days after  the informal conference.                                                                  |
| after         | If,  after the informal conference, FDA accepts the PMA for                                                                                   |
| within        | FDA has not determined whether the device falls within  the scope of &#167;&#8201;814.1(c).                                                   |
| after         | FDA will begin substantive review of a PMA after  the PMA is accepted for filing under &#167;&#8201;814.42.                                   |
| before        | review the PMA in accordance with part 14. before                                                                                             |
| within        | and the advisory committee report and recommendation and, within the later of 180 days from the date                                          |
| after         | PMA under &#167;&#8201;814.42 or the number of days after the date of filing as determined under &#167;&#8201;814.37(c),                      |
| exactly       | upon the applicant incorporating the specified labeling changes exactly as directed and upon the applicant submitting to                      |
| before        | FDA a copy of the final printed labeling before  marketing.                                                                                   |
| after         | FDA will publish in the Federal Register  after each quarter a list of the approvals announced                                                |
| within        | writing to a written request for an amendment within 180 days after the date FDA issues such                                                  |
| after         | written request for an amendment within 180 days after the date FDA issues such request; (2) The                                              |
| within        | writing to a written request for an amendment within 180 days after the date FDA issues such                                                  |
| after         | written request for an amendment within 180 days after the date FDA issues such request; (2) The                                              |
| before        | submitted in the PMA or any other information before the agency, FDA determines that any of the                                               |
| after         | FDA will publish in the Federal Register  after each quarter a list of the denials announced                                                  |
| after         | issue an order denying approval of a PMA after an approvable or not approvable letter has been                                                |
| before        | opportunity for an informal hearing under part 16. before                                                                                     |
| after         | applicant does not request a hearing or if after the part 16 hearing is held the agency                                                       |
| within        | the PMA holder's failure to request a hearing within the timeframe specified by FDA in the notice                                             |
| after         | does not request a regulatory hearing or if, after  the hearing, and                                                                          |
| after         | does not request a regulatory hearing or if, after  the hearing, and                                                                          |
| within        | a PMA, the agency shall proceed expeditiously, but within 60 days, to hold a hearing on whether                                               |
| after         | If,  after reviewing the summary and bibliography, FDA concludes that                                                                         |
| prior to      | not necessary to identify any device identifier discontinued prior to  December 23, 2013.                                                     |
| more than     | conditions that affect or are manifested in not more than  8,000 individuals in the United States per year.                                   |
| after         | may suspend or withdraw approval of an HDE after providing notice and an opportunity for an informal                                          |
| prior to      | designation to FDA's Office of Orphan Products Development. prior to                                                                          |
| more than     | condition that affects or is manifested in not more than  8,000 people in the United States per year.                                         |
| more than     | diagnostic purposes, the documentation must demonstrate that not more than 8,000 patients per year would be subjected to                      |
| within        | pending further review upon submission of additional information. within                                                                      |
| more than     | or diagnose affects or is manifested in not more than 8,000 people in the United States per year;                                             |
| more than     | or diagnose affects or is manifested in not more than 8,000 people in the United States per year;                                             |
| within        | not reside or have a place of business within the United States, the HDE shall be countersigned                                               |
| more than     | for the device and, if the amount is more than $250, a report by an independent certified public                                              |
| exceed        | organization, verifying that the amount charged does not exceed the costs of the device's research, development, fabrication,                 |
| within        | written response to FDA's request is not received within 75 days of the date of the request,                                                  |
| after         | shall comply with requirements set forth in &#167;&#8201;814.110. after                                                                       |
| within        | the applicant whether the application has been filed. within                                                                                  |
| after         | Within 75 days  after receipt of an HDE that is accepted for                                                                                  |
| after         | FDA will begin substantive review of an HDE  after  the HDE is accepted for filing under &#167;&#8201;814.112.                                |
| within        | HDE and the advisory committee report and recommendations within 75 days from receipt of an HDE that                                          |
| within        | order denying approval of the application under &#167;&#8201;814.118(a). within                                                               |
| exactly       | upon the applicant incorporating the specified labeling changes exactly as directed and upon the applicant submitting to                      |
| before        | FDA a copy of the final printed labeling before  marketing.                                                                                   |
| within        | writing to a written request for an amendment within 75 days after the date FDA issues such                                                   |
| after         | written request for an amendment within 75 days after the date FDA issues such request; (2) The                                               |
| within        | writing to a written request for an amendment within 75 days after the date FDA issues such                                                   |
| after         | written request for an amendment within 75 days after the date FDA issues such request; (2) The                                               |
| before        | submitted in the HDE or any other information before the agency, FDA determines that: (1) There is                                            |
| after         | issue an order denying approval of an HDE after an approvable or not approvable letter has been                                               |
| before        | with notice in accordance with &#167;&#8201;814.46(e), as applicable. before                                                                  |
| within        | In such an emergency situation, the physician shall,  within 5 days after the use of the device,                                              |
| after         | emergency situation, the physician shall, within 5 days after the use of the device, provide written notification                             |
| within        | use of a HUD by a reviewing IRB within 5 working days after being notified of the                                                             |
| after         | by a reviewing IRB within 5 working days after  being notified of the withdrawal of approval.                                                 |
| exceeds       | H and, if the number shipped or sold exceeds 8,000, an explanation and estimate of the number                                                 |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | (j) 30-day PMA supplement means a supplemental application to an approved PMA in accordance with &#167;&#8201;814.39(e).                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 21.0 year  | (s) Pediatric patients means patients who are 21 years of age or younger (that is, from birth through the twenty-first year of life, up to but not including the twenty-second birthday) at the time of the diagnosis or treatment.                                                                                                                                                                                                                                                                                                                          |
| 21 year    | (s) Pediatric patients means patients who are 21 years of age or younger (that is, from birth through the twenty-first year of life, up to but not including the twenty-second birthday) at the time of the diagnosis or treatment.                                                                                                                                                                                                                                                                                                                          |
| 20 second  | (s) Pediatric patients means patients who are 21 years of age or younger (that is, from birth through the twenty-first year of life, up to but not including the twenty-second birthday) at the time of the diagnosis or treatment.                                                                                                                                                                                                                                                                                                                          |
| 180.0 day  | FDA will consider a PMA abandoned if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (i)(A) The applicant fails to respond to a request for additional information within 180 days after the date FDA issues the request or                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (B) Other circumstances indicate that further work is not being undertaken with respect to it, and                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) The applicant fails to communicate with FDA within 7 days after the date on which FDA notifies the applicant that the PMA appears to have been abandoned.                                                                                                                                                                                                                                                                                                                                                                                 |
| 7.0 day    | FDA will consider a PMA abandoned if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (i)(A) The applicant fails to respond to a request for additional information within 180 days after the date FDA issues the request or                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (B) Other circumstances indicate that further work is not being undertaken with respect to it, and                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) The applicant fails to communicate with FDA within 7 days after the date on which FDA notifies the applicant that the PMA appears to have been abandoned.                                                                                                                                                                                                                                                                                                                                                                                 |
| 5.0 year   | If a master file is not referenced within 5 years after the date that it is submitted to FDA, FDA will return the master file to the person who submitted it.                                                                                                                                                                                                                                                                                                                                                                                                |
| 3.0 month  | The applicant shall submit these reports&#8212;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (1) 3 months after the filing date,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 180.0 day  | FDA may extend the time required for its review of the PMA, or PMA supplement, as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (1) If the applicant on its own initiative or at FDA's request submits a major PMA amendment (e.g., an amendment that contains significant new data from a previously unreported study, significant updated data from a previously reported study, detailed new analyses of previously submitted data, or significant required information previously omitted), the review period may be extended up to 180 days.                                                                                                                              |
| 180.0 day  | If FDA requests an applicant to submit a PMA amendment and a written response to FDA's request is not received within 180 days of the date of the request, FDA will consider the pending PMA or PMA supplement to be withdrawn voluntarily by the applicant.                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | FDA will require that a change for which a PMA supplement under paragraph (a) is not required be reported to FDA in:                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (i) A periodic report under &#167;&#8201;814.84 or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) A 30-day PMA supplement under this paragraph.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 30.0 day   | (2) FDA will identify, in the advisory opinion or correspondence, the type of information that is to be included in the report or 30-day PMA supplement.                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | If the change is required to be reported in a 30-day PMA supplement, the change may be made 30 days after FDA files the 30-day PMA supplement unless FDA requires the PMA holder to provide additional information, informs the PMA holder that the supplement is not approvable, or disapproves the supplement.                                                                                                                                                                                                                                             |
| 30.0 day   | If the change is required to be reported in a 30-day PMA supplement, the change may be made 30 days after FDA files the 30-day PMA supplement unless FDA requires the PMA holder to provide additional information, informs the PMA holder that the supplement is not approvable, or disapproves the supplement.                                                                                                                                                                                                                                             |
| 30.0 day   | If the change is required to be reported in a 30-day PMA supplement, the change may be made 30 days after FDA files the 30-day PMA supplement unless FDA requires the PMA holder to provide additional information, informs the PMA holder that the supplement is not approvable, or disapproves the supplement.                                                                                                                                                                                                                                             |
| 30.0 day   | The 30-day PMA supplement shall follow the instructions in the correspondence or advisory opinion.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | Any 30-day PMA supplement that does not meet the requirements of the correspondence or advisory opinion will not be filed and, therefore, will not be deemed approved 30 days after receipt.                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | Any 30-day PMA supplement that does not meet the requirements of the correspondence or advisory opinion will not be filed and, therefore, will not be deemed approved 30 days after receipt.                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | (f) Under section 515(d) of the act, modifications to manufacturing procedures or methods of manufacture that affect the safety and effectiveness of a device subject to an approved PMA do not require submission of a PMA supplement under paragraph (a) of this section and are eligible to be the subject of a 30-day notice.                                                                                                                                                                                                                            |
| 30.0 day   | A 30-day notice shall describe in detail the change, summarize the data or information supporting the change, and state that the change has been made in accordance with the requirements of part 820 of this chapter.                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | The manufacturer may distribute the device 30 days after the date on which FDA receives the 30-day notice, unless FDA notifies the applicant within 30 days from receipt of the notice that the notice is not adequate.                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | The manufacturer may distribute the device 30 days after the date on which FDA receives the 30-day notice, unless FDA notifies the applicant within 30 days from receipt of the notice that the notice is not adequate.                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | The manufacturer may distribute the device 30 days after the date on which FDA receives the 30-day notice, unless FDA notifies the applicant within 30 days from receipt of the notice that the notice is not adequate.                                                                                                                                                                                                                                                                                                                                      |
| 135.0 day  | If the notice is not adequate, FDA shall inform the applicant in writing that a 135-day PMA supplement is needed and shall describe what further information or action is required for acceptance of such change.                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | The number of days under review as a 30-day notice shall be deducted from the 135-day PMA supplement review period if the notice meets appropriate content requirements for a PMA supplement.                                                                                                                                                                                                                                                                                                                                                                |
| 135.0 day  | The number of days under review as a 30-day notice shall be deducted from the 135-day PMA supplement review period if the notice meets appropriate content requirements for a PMA supplement.                                                                                                                                                                                                                                                                                                                                                                |
| 180.0 day  | Within 180 days after receipt of an application that is accepted for filing and to which the applicant does not submit a major amendment, FDA will review the PMA and, after receiving the report and recommendation of the appropriate FDA advisory committee, send the applicant an approval order under &#167;&#8201;814.44(d), an approvable letter under &#167;&#8201;814.44(e), a not approvable letter under &#167;&#8201;814.44(f), or an order denying approval under &#167;&#8201;814.45.                                                          |
| 45.0 day   | Within 45 days after a PMA is received by FDA, the agency will notify the applicant whether the application has been filed.                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 180.0 day  | The 180-day period for review of a PMA starts on the date of filing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 180.0 day  | (c) FDA will complete its review of the PMA and the advisory committee report and recommendation and, within the later of 180 days from the date of filing of the PMA under &#167;&#8201;814.42 or the number of days after the date of filing as determined under &#167;&#8201;814.37(c), issue an approval order under paragraph (d) of this section, an approvable letter under paragraph (e) of this section, a not approvable letter under paragraph (f) of this section, or an order denying approval of the application under &#167;&#8201;814.45(a). |
| 180.0 day  | (g) FDA will consider a PMA to have been withdrawn voluntarily if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (1) The applicant fails to respond in writing to a written request for an amendment within 180 days after the date FDA issues such request;                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (2) The applicant fails to respond in writing to an approvable or not approvable letter within 180 days after the date FDA issues such letter; or                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (3) The applicant submits a written notice to FDA that the PMA has been withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 180.0 day  | (g) FDA will consider a PMA to have been withdrawn voluntarily if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (1) The applicant fails to respond in writing to a written request for an amendment within 180 days after the date FDA issues such request;                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (2) The applicant fails to respond in writing to an approvable or not approvable letter within 180 days after the date FDA issues such letter; or                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (3) The applicant submits a written notice to FDA that the PMA has been withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 60.0 day   | If FDA issues an order temporarily suspending approval of a PMA, the agency shall proceed expeditiously, but within 60 days, to hold a hearing on whether to permanently withdraw approval of the PMA in accordance with section 515(e)(1) of the act and the procedures set out in &#167;&#8201;814.46.                                                                                                                                                                                                                                                     |
| 45.0 day   | Within 45 days of receipt of a request for HUD designation, FDA will take one of the following actions:                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (1) Approve the request and notify the applicant that the device has been designated as a HUD based on the information submitted;                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (2) Return the request to the applicant pending further review upon submission of additional information.                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 45.0 day   | Upon receipt of this additional information, the review period may be extended up to 45 days; or                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (3) Disapprove the request for HUD designation based on a substantive review of the information submitted.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 75.0 day   | If FDA requests an HDE applicant to submit an HDE amendment, and a written response to FDA's request is not received within 75 days of the date of the request, FDA will consider the pending HDE or HDE supplement to be withdrawn voluntarily by the applicant.                                                                                                                                                                                                                                                                                            |
| 75.0 day   | Furthermore, if the HDE applicant, on its own initiative or at FDA's request, submits a major amendment as described in &#167;&#8201;814.37(c)(1), the review period may be extended up to 75 days.                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | Within 30 days from the date an HDE is received by FDA, the agency will notify the applicant whether the application has been filed.                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 75.0 day   | (b) The provisions contained in &#167;&#8201;814.42(b), (c), and (d) regarding notification of filing decisions, filing dates, the start of the 75-day review period, and applicant's options in response to FDA refuse to file decisions shall apply to HDE's.                                                                                                                                                                                                                                                                                              |
| 75.0 day   | Within 75 days after receipt of an HDE that is accepted for filing and to which the applicant does not submit a major amendment, FDA shall send the applicant an approval order, an approvable letter, a not approvable letter (under &#167;&#8201;814.116), or an order denying approval (under &#167;&#8201;814.118).                                                                                                                                                                                                                                      |
| 75.0 day   | If the HDE is referred to a panel, the agency shall follow the procedures set forth under &#167;&#8201;814.44, with the exception that FDA will complete its review of the HDE and the advisory committee report and recommendations within 75 days from receipt of an HDE that is accepted for filing under &#167;&#8201;814.112 or the date of filing as determined under &#167;&#8201;814.106, whichever is later.                                                                                                                                        |
| 75.0 day   | The applicant may respond to the not approvable letter in the same manner as permitted for not approvable letters for PMA's under &#167;&#8201;814.44(f), with the exception that if a major HDE amendment is submitted, the review period may be extended up to 75 days.                                                                                                                                                                                                                                                                                    |
| 75.0 day   | (e) FDA will consider an HDE to have been withdrawn voluntarily if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (1) The applicant fails to respond in writing to a written request for an amendment within 75 days after the date FDA issues such request;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) The applicant fails to respond in writing to an approvable or not approvable letter within 75 days after the date FDA issues such letter; or                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (3) The applicant submits a written notice to FDA that the HDE has been withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 75.0 day   | (e) FDA will consider an HDE to have been withdrawn voluntarily if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (1) The applicant fails to respond in writing to a written request for an amendment within 75 days after the date FDA issues such request;                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) The applicant fails to respond in writing to an approvable or not approvable letter within 75 days after the date FDA issues such letter; or                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (3) The applicant submits a written notice to FDA that the HDE has been withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 5.0 day    | In such an emergency situation, the physician shall, within 5 days after the use of the device, provide written notification to the chairman of the IRB of such use.                                                                                                                                                                                                                                                                                                                                                                                         |


## Condition

| Condition      | Context                                                                                                                                              |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------|
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                                   |
| unless         | part applies to any class III medical device, unless exempt under section 520(g) of the act, that:                                                   |
| if             | be a false statement of material fact, even if the statement was not intended by the person                                                          |
| if             | new analyses of previously submitted data (e.g., meta-analyses) if the studies, events or analyses reveal risks of                                   |
| when           | that identifies one or more of the following when included on the label of the device: (i)                                                           |
| unless         | an approval order is issued to the applicant unless  it previously has been publicly disclosed or acknowledged.                                      |
| if             | PMA file are not available for public disclosure. if                                                                                                 |
| if             | available for public disclosure before such order issues. if                                                                                         |
| if             | an order denying approval of the PMA issues if disclosure is relevant to public consideration of a                                                   |
| unless         | (2) Any protocol for a test or study  unless the protocol is shown to constitute trade secret                                                        |
| unless         | (5) An assay method or other analytical method,  unless it does not serve any regulatory purpose and                                                 |
| if             | to the public are available for public disclosure if any one of the following events occurs and                                                      |
| unless         | PMA file are not available for public disclosure unless they have been previously disclosed to the public,                                           |
| if             | for approval under this part may be approved if : (1) The foreign data are applicable to                                                             |
| when           | meet with FDA officials in a &#8220;presubmission&#8221; meeting when approval based solely on foreign data will be                                  |
| unless         | (1) The name and address of the applicant. unless                                                                                                    |
| if             | description of the manufacturing process should be included if  it will sign                                                                         |
| if             | description of the foreign and U.S. marketing history, if any, of the device, including a list of                                                    |
| if             | marketing of the device by the applicant and, if known, the history of the marketing of the                                                          |
| if             | the functional components or ingredients of the device if the device consists of more than one physical                                              |
| where          | used for, the manufacture, processing, packing, storage, and, where appropriate, installation of the device, in sufficient detail                    |
| if             | was conducted in compliance with part 58, or, if the study was not conducted in compliance with                                                      |
| not subject to | in part 56 of this chapter, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105, and that                         |
| if             | regulations in part 50 of this chapter; or if the investigation was not conducted in compliance with                                                 |
| if             | sponsors of clinical investigations and clinical investigators, or if the investigation was not conducted in compliance with                         |
| if             | possession of or reasonably obtainable by the applicant if  an FDA advisory committee or FDA requests.                                               |
| if             | more samples of the device and its components, if  requested by FDA.                                                                                 |
| unless         | &#167;&#8201;25.20(n) prepared in the applicable format in &#167;&#8201;25.40, unless the action qualifies for exclusion under &#167;&#8201;25.30 or |
| if             | The application must include the following information,  if readily available: (i) A description of any pediatric                                    |
| unless         | will not be considered part of a PMA unless such reference is authorized in writing by the                                                           |
| if             | the applicant shall submit a statement that ident if ies the omitted information and just                                                            |
| unless         | due to the submission of an update report unless  the update is a major amendment under &#167;&#8201;814.37(c)(1).                                   |
| if             | may be submitted as part of the PMA. if                                                                                                              |
| subject to     | (f) If a color additive  subject to section 721 of the act is used in                                                                                |
| subject to     | device that contains a color additive that is subject to section 721 of the act will not be                                                          |
| until          | 721 of the act will not be approved until the color additive is listed for use in                                                                    |
| if             | Document Mail Center, 10903 New Hampshire Ave., Bldg. if                                                                                             |
| if             | supplement number assigned to the original submission and, if submitted on the applicant's own initiative, the reason                                |
| if             | PMA amendment (e.g., an amendment that contains sign if icant new data from a previously unreported study,                                           |
| if             | written response declining to submit the requested amendment. if                                                                                     |
| unless         | for which the applicant has an approved PMA, unless the change is of a type for which                                                                |
| if             | not limited to, the following types of changes if they affect the safety or effectiveness of the                                                     |
| if             | for the device without submitting a PMA supplement if the change does not affect the device's safety                                                 |
| when           | operation, or physical layout of the device, or when  otherwise required by FDA.                                                                     |
| if             | applicant shall submit additional copies and additional information if  requested by FDA.                                                            |
| if             | previous application or submission that contains the information. if                                                                                 |
| if             | However,  if additional information required under &#167;&#8201;814.20(b)(13) has become readily                                                     |
| if             | FDA will ident if y such a change in an advisory opinion                                                                                             |
| if             | FDA will ident if y such a change in an advisory opinion                                                                                             |
| unless         | days after FDA files the 30-day PMA supplement unless FDA requires the PMA holder to provide additional                                              |
| subject to     | affect the safety and effectiveness of a device subject to an approved PMA do not require submission of                                              |
| unless         | date on which FDA receives the 30-day notice, unless FDA notifies the applicant within 30 days from                                                  |
| if             | deducted from the 135-day PMA supplement review period if the notice meets appropriate content requirements for a                                    |
| if             | agency will file the PMA and will not if y the applicant in writing of the filing.                                                                   |
| if             | to file a PMA, the agency will not if y the applicant of the reasons for the                                                                         |
| if             | section 515(c)(1) (A)-(G) of the act and &#167;&#8201;814.20. if                                                                                     |
| if             | (e) FDA may refuse to file a PMA  if  any of the following applies:                                                                                  |
| unless         | will do so upon request of an applicant, unless FDA determines that the application substantially duplicates information                             |
| if             | to the applicant an order approving a PMA if none of the reasons in &#167;&#8201;814.45 for denying                                                  |
| if             | application on the basis of draft final labeling if the only deficiencies in the application concern editorial                                       |
| if             | FDA will send the applicant an approvable letter if the application substantially meets the requirements of this                                     |
| if             | FDA will send the applicant an approvable letter if the application substantially meets the requirements of this                                     |
| if             | approval: (i) The submission of certain information ident if ied in the approvable letter, e.g., final labeling;                                     |
| if             | will send the applicant a not approvable letter if the agency believes that the application may not                                                  |
| where          | under section 515(d)(2) (A)-(E) of the act, and, where practical, will identify measures required to place the                                       |
| if             | issue an order denying approval of a PMA if the applicant fails to follow the requirements of                                                        |
| if             | issue an order denying approval of a PMA if the applicant fails to follow the requirements of                                                        |
| if             | no reason for the noncompliance is provided or, if  it is, the d                                                                                     |
| subject to     | investigation involving human subjects described in the PMA, subject to the institutional review board regulations in part 56                        |
| where          | act and the regulations under this part, and, where practical, will identify measures required to place the                                          |
| if             | issue an order withdrawing approval of a PMA if , from any information available to the agency,                                                      |
| if             | no reason for the noncompliance is provided or, if  it is, the d                                                                                     |
| subject to     | investigation involving human subjects described in the PMA, subject to the institutional review board regulations in part 56                        |
| if             | the applicant does not request a hearing or if after the part 16 hearing is held the                                                                 |
| if             | the applicant does not request a hearing or if after the part 16 hearing is held the                                                                 |
| if             | an order temporarily suspending approval of a PMA if FDA determines that there is a reasonable probability                                           |
| if             | an order temporarily suspending approval of the PMA. if                                                                                              |
| subject to     | probability that the continued distribution of a device subject to an approved PMA would cause serious, adverse health                               |
| if             | holder does not request a regulatory hearing or if , after the hearing, and after consideration of                                                   |
| if             | (4) Inclusion of ident if ication codes on the device or its labeling,                                                                               |
| if             | submit to FDA information needed to trace patients if such information is necessary to protect the public                                            |
| unless         | Unless FDA specifies otherwise, any periodic report shall: unless                                                                                    |
| if             | This action will ensue  if the request is incomplete because it does not                                                                             |
| if             | FDA may revoke a HUD designation  if the agency finds that: (1) The request for                                                                      |
| unless         | of why the device would not be available unless an HDE were granted and a statement that                                                             |
| if             | amount to be charged for the device and, if the amount is more than $250, a report                                                                   |
| if             | Furthermore,  if the HDE applicant, on its own initiative or                                                                                         |
| if             | FDA may refuse to file an HDE  if any of the following applies: (1) The application                                                                  |
| unless         | do so upon the request of an applicant, unless FDA determines that the application substantially duplicates information                              |
| if             | to the applicant an order approving an HDE if none of the reasons in &#167;&#8201;814.118 for denying                                                |
| if             | application on the basis of draft final labeling if the only deficiencies in the application concern editorial                                       |
| if             | FDA will send the applicant an approvable letter  if the application substantially meets the requirements of this                                    |
| if             | FDA will send the applicant an approvable letter  if the application substantially meets the requirements of this                                    |
| if             | approval: (1) The submission of certain information ident if ied in the approvable letter, e.g., final labeling;                                     |
| if             | will send the applicant a not approvable letter if the agency believes that the application may not                                                  |
| where          | will describe the deficiencies in the application and, where practical, will identify measures required to place the                                 |
| if             | for PMA's under &#167;&#8201;814.44(f), with the exception that if a major HDE amendment is submitted, the review                                    |
| if             | deny approval or withdraw approval of an application if the applicant fails to meet the requirements of                                              |
| if             | deny approval or withdraw approval of an application if , upon the basis of the information submitted                                                |
| if             | deny approval or withdraw approval of an application if , upon the basis of the information submitted                                                |
| subject to     | investigation involving human subjects described in the HDE, subject to the institutional review board regulations in part 56                        |
| if             | for PMA's under &#167;&#8201;814.45(b) and (d), as applicable. if                                                                                    |
| subject to     | and contents of an HDE file shall be subject to the same rules that pertain to PMA's under                                                           |
| if             | In addition, a HUD may be administered only  if  such use has been approved by an IRB.                                                               |
| subject to     | HDE approved under this subpart H shall be subject to the postapproval requirements and reports set forth under                                      |
| if             | Unless FDA spec if ies otherwise, any periodic report shall include: (i)                                                                             |


## Entities

| Entities       | Context                                                                                                                                               |
|:---------------|:------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food           | Food  and Drugs.                                                                                                                                      |
| Scope          | Scope .                                                                                                                                               |
| Purpose        | Purpose .                                                                                                                                             |
| Serious        | (l)  Serious , adverse health consequences means any significant adverse                                                                              |
| United States  | in not more than 8,000 individuals in the United States  per year.                                                                                    |
| Unique         | (q)  Unique device identifier (UDI) means an identifier that adequately                                                                               |
| United States  | identify an item sold at retail in the United States .                                                                                                |
| Docket Number  | IDE that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305),                                          |
| Rockville, MD  | 1-23,  Rockville, MD 20857, for investigations involving an exception from informed                                                                   |
| Research       | Research  conducted outside the United States.                                                                                                        |
| United States  | Research conducted outside the  United States .                                                                                                       |
| United States  | If data from clinical investigations conducted outside the  United States are submitted to support a PMA, the applicant                               |
| U.S            | (1) The foreign data are applicable to the U.S . population and                                                                                       |
| U.S            | (1) The foreign data are applicable to the U.S . population and                                                                                       |
| Product        | Product  development protocol (PDP).                                                                                                                  |
| Application    | Application .                                                                                                                                         |
| United States  | or have a place of business within the United States , the PMA shall be countersigned by an                                                           |
| United States  | or have a place of business within the United States , the PMA shall be countersigned by an                                                           |
| U.S            | A brief description of the foreign and  U.S . marketing history, if any, of the device,                                                               |
| Explain        | (ii)  Explain  any deviation from a voluntary standard.                                                                                               |
| Information    | Information on nonclinical laboratory studies shall include a statement                                                                               |
| Information    | Information on clinical investigations involving human subjects shall include                                                                         |
| United States  | following: (A) For clinical investigations conducted in the United States , a statement with respect to each investigation                            |
| Failure        | Failure or inability to comply with these requirements does                                                                                           |
| United States  | (B) For clinical investigations conducted in the  United States , a statement that each investigation was conducted                                   |
| Failure        | Failure or inability to comply with these requirements does                                                                                           |
| United States  | (C) For clinical investigations conducted outside the  United States that are intended to support the PMA, the                                        |
| Failure        | Failure or inability to comply with these requirements does                                                                                           |
| Such           | Such labeling may include, e.g., instructions for installation and                                                                                    |
| G609           | G609 , Silver Spring, MD 20993-0002.                                                                                                                  |
| Research       | regulated by the Center for Biologics Evaluation and Research , send it to: Food and Drug Administration,                                             |
| Research       | regulated by the Center for Biologics Evaluation and Research , send it to: Food and Drug Administration,                                             |
| Rm             | 71,  Rm .                                                                                                                                             |
| G112           | G112 , Silver Spring, MD 20993-0002.                                                                                                                  |
| Research       | regulated by the Center for Drug Evaluation and Research , send it to: Central Document Control Room,                                                 |
| Research       | regulated by the Center for Drug Evaluation and Research , send it to: Central Document Control Room,                                                 |
| Beltsville, MD | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                                             |
| New            | the safety or effectiveness of the device: (1) New  indications for use of the device.                                                                |
| Research       | Director of the Center for Biologics Evaluation and Research , or the Director of the Center for                                                      |
| Research       | Director of the Center for Biologics Evaluation and Research , or the Director of the Center for                                                      |
| Such           | Such approval will be conditioned upon the applicant incorporating                                                                                    |
| Rockville, MD  | 1061,  Rockville, MD  20852.                                                                                                                          |
| Denial         | Denial  of approval of a PMA.                                                                                                                         |
| Postapproval   | Postapproval  requirements.                                                                                                                           |
| Batch          | (8)  Batch  testing of the device.                                                                                                                    |
| Purpose        | Purpose  and scope.                                                                                                                                   |
| United States  | in not more than 8,000 individuals in the United States  per year.                                                                                    |
| Research       | Health (CDRH), the Center for Biologics Evaluation and Research  (CBER), or the Center for Drug Evaluation and                                        |
| Research       | Health (CDRH), the Center for Biologics Evaluation and Research  (CBER), or the Center for Drug Evaluation and                                        |
| United States  | in not more than 8,000 people in the United States  per year.                                                                                         |
| United States  | subjected to diagnosis by the device in the United States .                                                                                           |
| United States  | prevalence of the disease or condition in the United States by providing credible conclusions from appropriate research or                            |
| United States  | in not more than 8,000 people in the United States per year; (ii) FDA determines that, for a                                                          |
| United States  | in not more than 8,000 people in the United States per year; (ii) FDA determines that, for a                                                          |
| Rockville, MD  | (HF-35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD  20857.                                                                       |
| United States  | (a)  United States  applicant or representative.                                                                                                      |
| United States  | or have a place of business within the United States , the HDE shall be countersigned by an                                                           |
| United States  | or have a place of business within the United States , the HDE shall be countersigned by an                                                           |
| United States  | devices or alternative forms of treatment in the United States ; (3) An explanation of why the probable                                               |
| Such           | Such explanation shall include a description, explanation, or theory                                                                                  |
| United States  | with respect to clinical investigations conducted in the United States and the information described in &#167;&#8201;814.20(b)(6)(ii)(C) with respect |
| United States  | with respect to clinical investigations conducted in the United States and the information described in &#167;&#8201;814.20(b)(6)(ii)(C) with respect |
| G609           | G609 , Silver Spring, MD 20993-0002.                                                                                                                  |
| Research       | regulated by the Center for Biologics Evaluation and Research , send this information to the Food and                                                 |
| Research       | regulated by the Center for Biologics Evaluation and Research , send this information to the Food and                                                 |
| Rm             | 71,  Rm .                                                                                                                                             |
| G112           | G112 , Silver Spring, MD 20993-0002.                                                                                                                  |
| Research       | regulated by the Center for Drug Evaluation and Research , send this information to the Central Document                                              |
| Research       | regulated by the Center for Drug Evaluation and Research , send this information to the Central Document                                              |
| Beltsville, MD | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                                             |
| New            | New  indications for use.                                                                                                                             |
| Such           | Such approval will be conditioned upon the applicant incorporating                                                                                    |
| Denial         | Denial of approval or withdrawal of approval of an                                                                                                    |
| Disclosure     | Disclosure by FDA of the existence and contents of                                                                                                    |
| Postapproval   | Postapproval  requirements and reports.                                                                                                               |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (c) This part applies to any class III medical device, unless exempt under section 520(g) of the act, that:                                                                                                                                                                                                                                       |
|            |               (1) Was not on the market (introduced or delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent to a device on the market before May 28, 1976, or to a device first marketed on, or after that date, which has been classified into class I or class II; or |
| 1976-05-28 | (c) This part applies to any class III medical device, unless exempt under section 520(g) of the act, that:                                                                                                                                                                                                                                       |
|            |               (1) Was not on the market (introduced or delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent to a device on the market before May 28, 1976, or to a device first marketed on, or after that date, which has been classified into class I or class II; or |
| 1976-05-28 | (2) Is required to have an approved premarket approval application (PMA) or a declared completed product development protocol under a regulation issued under section 515(b) of the act; or                                                                                                                                                       |
|            |               (3) Was regulated by FDA as a new drug or antibiotic drug before May 28, 1976, and therefore is governed by section 520(1) of the act.                                                                                                                                                                                              |
| 2018-01-23 | 1-23, Rockville, MD 20857, for investigations involving an exception from informed consent under &#167;&#8201;50.24 of this chapter.                                                                                                                                                                                                              |
| 1971-05-01 | (f) If a color additive subject to section 721 of the act is used in or on the device and has not previously been listed for such use, then, in lieu of submitting a color additive petition under part 71, at the option of the applicant, the information required to be submitted under part 71 may be submitted as part of the PMA.           |
| 2013-12-23 | It is not necessary to identify any device identifier discontinued prior to December 23, 2013.                                                                                                                                                                                                                                                    |


